KYNTRA BIO, INC.
| Revenue | $2.3M |
|---|---|
| Operating income | $-31.4M |
| Net income | $-3.2M |
| Free cash flow | $-17.9M |
| Operating margin | -1386.6% |
| Net margin | -142.4% |
| Period | 2026 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
speculative hold/watch, not a buy on this call.
Kyntra has $95.7 million in cash and expects runway into 2028, but the $12.0 million profit was driven by a non-cash subsidiary deconsolidation while revenue was negative $1.5 million and operating expenses rose to $16.1 million. The investment case rests on unvalidated clinical execution: FG-3246 showed encouraging early activity—8.7-month monotherapy rPFS and 10.1 months with enzalutamide after one prior ARPI—but the key 36-patient Phase II interim readout is not due until Q4 2026, with mature rPFS extending into 2027.
Near term
The Q4 2026 FG-3246 Phase II interim analysis is the principal near-term catalyst; investors need PSA50 response, ORR, safety, dose-response, PK, and results by prior Pluvicto exposure—not just management's targeted rPFS threshold of 10 months or greater.
The trial is testing 75 patients across 1.8, 2.4, and 2.7 mg/kg with G-CSF prophylaxis. This could improve treatment continuity versus Phase I, but it also makes cross-trial comparisons with the heavily pre-treated 8.7-month rPFS population unreliable.
Approximately 30% of randomized Phase II patients had prior Lutetium-177 exposure. That subgroup could determine whether FG-3246 is genuinely differentiated after PSMA-directed therapy, but management has not disclosed subgroup efficacy.
Roxadustat Phase III initiation is targeted for Q4 2026, but internal development would require additional capital and partnering remains unresolved.
Longer term
FG-3246's commercial positioning depends on whether CD46 targeting is complementary to or displaced by PSMA-directed therapies. Management's view that physicians may sequence a different modality after PSMA radioligand therapy was based on limited KOL discussion, not clinical evidence.
The companion FG-3180 PET agent could enable biomarker enrichment and create diagnostic economics, but the company still needs to establish that CD46 uptake predicts clinical response prospectively. The prior association between uptake and PSA50 response was small-sample and narrowly missed statistical significance.
Roxadustat could address a sizable lower-risk MDS population, particularly RS- patients, but the supporting 36% versus 7% transfusion-independence result is a post hoc MATTERHORN analysis. Phase III success, durability, safety, and commercial differentiation remain unproven.
If partnered, AstraZeneca would receive 35% of economics accruing to Kyntra; if developed internally, Kyntra would owe a mid-single-digit royalty on net sales. This materially affects the program's eventual value and financing requirements.
Red flags
The reported $12.0 million net income is not evidence of operating profitability; revenue was negative $1.5 million and the earnings improvement was attributed to a non-cash subsidiary deconsolidation.
Management repeatedly framed FG-3246 as potentially improving on 8.7-month rPFS, but the Phase II is open-label, only 36 patients are included in the interim analysis, and mature rPFS will not be available until throughout 2027.
Tissue availability is limited in predominantly bone-only prostate cancer, constraining paired biopsy analyses needed to answer key questions about CD46, PSMA expression, and resistance. ctDNA and imaging may help, but their predictive value is not established.
The company did not provide enrollment detail beyond 30% prior Pluvicto exposure, leaving uncertainty around recruitment pace, balance across dose cohorts, and whether the study can support an accelerated-approval strategy.
The roxadustat Phase III program is not fully economically de-risked: management is evaluating a partner versus internal development, and internal execution requires new capital despite the stated runway into 2028.
The competitive thesis remains largely management- and anecdote-driven. No comparative trial data establish FG-3246's advantage over Pluvicto, other PSMA agents, chemotherapy, or emerging ADCs.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
Upcoming earnings
Earnings transcripts
Press & signals
- GlobeNewswire
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
- GlobeNewswire
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
- GlobeNewswire
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update